

University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln

Biochemistry -- Faculty Publications

Biochemistry, Department of

11-2018

Combining Mass Spectrometry and NMR Improves Metabolite Detection and Annotation

Fatema Bhinderwala

University of Nebraska - Lincoln, fbhinderwala2@unl.edu

Nishikant Wase

University of Nebraska-Lincoln, nishikant.wase@gmail.com

Concetta DiRusso

University of Nebraska - Lincoln, cdirusso2@unl.edu

Robert Powers

University of Nebraska - Lincoln, rpowers3@unl.edu

Follow this and additional works at: <https://digitalcommons.unl.edu/biochemfacpub>



Part of the [Biochemistry Commons](#), [Biotechnology Commons](#), and the [Other Biochemistry, Biophysics, and Structural Biology Commons](#)

Bhinderwala, Fatema; Wase, Nishikant; DiRusso, Concetta; and Powers, Robert, "Combining Mass Spectrometry and NMR Improves Metabolite Detection and Annotation" (2018). *Biochemistry -- Faculty Publications*. 469.

<https://digitalcommons.unl.edu/biochemfacpub/469>

This Article is brought to you for free and open access by the Biochemistry, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Biochemistry -- Faculty Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.



Published in final edited form as:

J Proteome Res. 2018 November 02; 17(11): 4017–4022. doi:10.1021/acs.jproteome.8b00567.

Combining Mass Spectrometry and NMR Improves Metabolite Detection and Annotation

Fatema Bhinderwala^{1,2}, Nishikant Wase², Concetta DiRusso^{2,3}, Robert Powers^{1,3,*}

¹Department of Chemistry, University of Nebraska-Lincoln, Lincoln, NE 68588-0304

²Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE 68588-0664

³Nebraska Center for Integrated Biomolecular Communication

Abstract

Despite inherent complementarity, nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry (MS) are routinely *separately* employed to characterize metabolomics samples. More troubling is the erroneous view that metabolomics is better served by exclusively utilizing MS. Instead, we demonstrate the importance of combining NMR and MS for metabolomics by using small chemical compound-treatments of *Chlamydomonas reinhardtii* as an illustrative example. A total of 102 metabolites were detected (82 by GC-MS, 20 by NMR and 22 by both techniques). Out of these 47 metabolites of interest were identified, where 14 metabolites were uniquely identified by NMR and 16 metabolites were uniquely identified by GC-MS. A total of 17 metabolites were identified by both NMR and GC-MS. In general, metabolites identified by both techniques exhibited similar changes upon compound treatment. In effect, NMR identified key metabolites that were missed by MS and enhanced the overall coverage of the oxidative pentose phosphate pathway, Calvin cycle, tricarboxylic acid cycle and amino acid biosynthetic pathways that informed on pathway activity in central carbon metabolism leading to fatty acid and complex lipid synthesis. Our study emphasizes a prime advantage of combining multiple analytical techniques - an improved detection and annotation of metabolites.

Graphical Abstract

* **Corresponding Author:** Robert Powers, University of Nebraska-Lincoln, rpowers3@unl.edu, Phone: (402) 472-3039, Fax: (402) 472-9402.

Author Contributions

FB and NW performed the experiments; RP and CD designed the experiments; FB, NW, CD, and RP analyzed the data and wrote the manuscript.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website. The supplemental information includes: Methods. Detailed description of the methods used for cell growth, compound treatment, metabolite extraction and data collection and analyses.

Figure S-1. PCA scores plot generated from the (A) NMR and (B) GC-MS datasets

Figure S-2. Individual line plots for all 22 metabolites identified by both NMR and GC-MS.

Figure S-3. Comparison of WD30030 and WD10784 induced metabolite changes using (A) NMR and (B) GC-MS datasets.


Table S-1. List of metabolites uniquely identified by GC-MS.

Table S-2. List of metabolites uniquely identified by NMR.

Table S-3. List of metabolites identified by both NMR and GC-MS.

Table S-4. Comparison of 47 metabolites of interest under both lipid inducing compound treatment against untreated controls.

The authors declare no competing financial interests.



Keywords

NMR; mass spectrometry; metabolomics; metabolite annotation; metabolite detection; Multiblock PCA

INTRODUCTION:

Metabolomics is experiencing exponential growth¹ and has made substantial contributions to various research areas, such as nutrition, plant physiology, cellular metabolism, disease diagnosis and biomarker detection, and drug discovery and development.^{2–45–6} To date, metabolomics has primarily relied on the separate application of mass spectrometry (MS) or nuclear magnetic resonance spectroscopy (NMR), but there are also notable examples of the application of surface enhanced Raman spectroscopy and Fourier-transform infrared spectroscopy (FTIR).⁷ Nevertheless, the vast majority of recently published metabolomics studies are only making use of GC-MS or LC-MS despite prior contributions from NMR and other analytical techniques.⁸ In 2017, only 5% of metabolomics manuscripts published in PubMed described any form of a combined NMR and GC-MS approach to metabolomics (Figure 1). This may be explained, in part, by an erroneous belief that mass spectrometry is the optimal analytical technique for metabolomics. Unfortunately, this false perspective has begun to negatively impact the field, and will likely limit the coverage of the metabolome, potentially diminish the quality of research, and hamper progress. Instead, metabolomics should seek to maximize (not limit) the number of analytical techniques used to characterize the entirety of the metabolome. Moreover, the confidence and accuracy of metabolite identification and quantification is improved by the application of multiple analytical techniques. Thus, the goal of the field should be to accurately address scientific questions by striving for the broadest coverage of the metabolome; not by focusing on the type of instrumentation used.

NMR and MS are inherently complementary due to their distinct strengths and weaknesses. This, in turn, leads to different sets of metabolites that are uniquely detected by NMR and

MS. Accordingly, combining both NMR and MS will result in a greater coverage of the metabolome. Simplistically, NMR detects the most abundant metabolites and MS detects the metabolites that are readily ionizable. This arises from fundamental differences between NMR and MS. For example, NMR requires minimal sample handling, but chromatography is a necessary component of MS metabolomics because of the relatively narrow molecular-weight distribution of the metabolome.⁹ Chromatography methods are plagued by non-uniform metabolite derivatization, incomplete column recovery, decomposition during derivatization, ion-suppression due to the co-eluent matrix, and or misaligned retention times to name a few.^{10–14} Similarly, small molecules exhibit variable thermal stability that may lead to the loss of metabolites and the erroneous accumulation of degradation products at temperatures routinely used for gas chromatography (GC).¹⁵ Conversely, NMR lacks the sensitivity to detect metabolites in the sub-micromolar range ($< 1 \mu\text{M}$) and has limited spectral resolution that often results in peak overlap.¹⁶ MS also has a higher resolution ($\sim 10^3$ to 10^4) and dynamic range ($\sim 10^3$ to 10^4) relative to NMR.

Ambiguous peak assignments are a common problem encountered by both NMR and MS. This issue is attributed to limitations in the availability of reference spectra, insufficient software and databases, and our incomplete knowledge of the metabolome. It is believed that nearly all metabolomics investigations have at least one misidentified or unidentified metabolite.¹⁷ Natural product chemistry has routinely employed protocols involving both NMR and MS data to identify novel compounds, but the application of this combinatorial approach has seen limited usage in metabolomics.¹⁸ Nevertheless, a few methods have recently been described that combine NMR and MS to assign metabolites and identify unknowns.^{19–21} Notably, the community has recognized that metabolomics needs to continue to move in this direction.^{8, 21–26} There have also been a few recent examples that highlight the utility and complementarity of combining 1D ^1H NMR with direct injection or LC/GC-MS experiments for metabolomics.^{27–28} Most of these examples are methodology driven, are focused on improving statistical tools and modeling, or performed parallel, but separate, sample analysis.^{29–31} In this regards, NMR is routinely only used as a supplement to MS or in a secondary confirmatory role. Accordingly, the full impact of using NMR to characterize a metabolomics sample is missed.

Current estimates suggest the size of the human metabolome is approximately 150,000 metabolites, but only upwards of a few hundred metabolites are typically identified in a given metabolomics study.³² Combining MS with NMR and other analytical techniques is necessary to move beyond this self-imposed limit.

To address this need, a global metabolomics study was performed in a platform-unbiased fashion to highlight the intrinsic benefits of combining NMR and MS. In this regard, NMR and MS data were collected on a similar set of samples without complicating existing workflows or requiring major protocol modifications. Accordingly, there were no serious experimental barriers encountered that would prevent the metabolomics community from adapting a combined NMR and MS approach as a standard for the field. As an illustrated example, the metabolome of *Chlamydomonas reinhardtii* grown in tris-acetate phosphate (TAP) media ($^{13}\text{C}_2$ -acetate for NMR) was characterized by NMR and GC-MS. The cells were also treated with two lipid accumulation modulators (WD30030 and WD10784) as

described by Wase *et al.*³³ The aqueous-extracted metabolomes from treated and untreated cells were then compared to identify metabolic variations due to the compound treatments. The eRah package was used to perform peak picking, retention time alignment and metabolite library search for the GC-MS dataset.^{33–34} Similarly, NMRpipe³⁵ and NMRviewJ³⁶ were used for processing and peak picking the NMR dataset and metabolite assignments were performed using spectral databases.³⁷ A schematic overview of the workflow is shown in Figure 2A. Details of data handling, processing and analyses are available as supplemental information.

The complete 2D ¹H-¹³C HSQC NMR spectra obtained from *C. reinhardtii* metabolome extracts were used for non-supervised multivariate analyses to generate a principal component analyses (PCA) scores plot with an associated dendrogram (Figure S-1A). Statistical models were generated after the data was processed as a matrix to be standard normal variate (SNV) normalized and unit variance scaled. The WD30030 and WD10784 treated cells formed distinct clusters separate from the untreated control. The dendrogram generated from the Mahalanobis distances between each point in the PCA scores plot and the resulting p-value between each node indicates a statistically significant ($p < 0.05$) separation between each group. Similarly, metabolite assignments from the GC-MS spectral dataset were obtained from the eRah package and identified using the GOLM database.³⁸ The assigned metabolite peak areas were then imported as a matrix into MVAPACK to obtain a comparable PCA scores plot and dendrogram as described above (Figure S-1B).³⁹ A similar statistically significant group separation between the WD30030/WD10784 treated cells and the untreated controls was obtained. Importantly, the NMR and GC-MS datasets were successfully combined to generate a comparable multiblock (MB)-PCA model with a corresponding dendrogram (Figure 2B).³⁰ The MB-PCA model provides a single statistical model for both datasets. In this manner, key metabolite differences between the treated and untreated controls can be identified irrespective of the analytical method.

Overall, 82 compounds were identified by GC-MS alone; 20 by NMR alone, and 22 were common to both methods (Tables S-1 to S-3). Of these 102 detected metabolites, a total of 47 metabolites of interest were perturbed upon compound treatment (Table S-4). Thus, a greater coverage of compound-induced changes in the *C. reinhardtii* metabolome was obtained by combining the metabolite assignments from the NMR and GC-MS datasets. Specifically, 14 unique metabolites were identified from the NMR analysis of ¹³C₂-acetate labeled *C. reinhardtii* cells that were significantly perturbed upon treatment with either WD30030/WD10784. Metabolites were assigned using the Biological Magnetic Resonance Bank (BMRB) metabolomics database.⁴⁰ Similarly, 16 unique metabolites were identified from the GC-MS spectra using the GOLM database. Furthermore, an additional 17 metabolites were identified by both NMR and GC-MS. In total, the metabolites comprise the following metabolic pathways: oxidative pentose phosphate pathway, Calvin cycle, tricarboxylic acid cycle and amino acid biosynthetic pathways. A summary of the *C. reinhardtii* metabolic changes of interest resulting from treatment with WD30030/WD10784 is shown in Figure 3.

NMR and GC-MS identified nine glycolytic intermediates, where fructose, glycerol and pyruvate were uniquely identified by NMR and fructose-6-phosphate was unique to GC-MS.

All 20 amino acids were detected from the combined datasets, but asparagine, cysteine, histidine, serine and tryptophan were only observed by GC-MS. Consequently, glycine, lysine, methionine, and valine were unique to NMR. Tricarboxylic acid cycle and Calvin cycle metabolites exhibited the most variation. Acetate, isocitrate, ketoglutarate, malate and succinate were identified by NMR, but fumarate was limited to GC-MS. Ribulose and its phosphate derivatives were exclusively assigned through GC-MS. Nucleotide and nucleoside analogs were the metabolite group consistently observed by both techniques. Seven out of the ten metabolites, 2-deoxy adenosine, adenosine, guanosine, hypoxanthine, inosine, thymine, and xanthosine were observed by both NMR and GC-MS. Cytosine and uridine were uniquely identified by NMR; whereas, uracil was only observed by GC-MS. A complete list of metabolites identified by NMR and GC are provided in the supplemental information (Tables S-1 to S-4).

The complete set of 22 metabolites identified by both NMR and GC-MS including the 17 metabolites of interest depicted in Figure 3 were further evaluated for overall consistency between the two methods. A correlation between the 22 common metabolites was evaluated using Pearson correlation within the R environment (<http://www.r-project.org>) and the resulting comparison is plotted in Figure 4. While there is significant scatter, the overall trend is quite similar. It is important to note that only relative changes in metabolite concentrations were compared. Furthermore, the GC-MS metabolomics analysis was untargeted and lacked any metabolite-specific calibration. Conversely, the absolute quantitation of metabolite concentration changes is an inherent strength of NMR. But, NMR was only used to monitor the relative changes in metabolites derived from $^{13}\text{C}_2$ -acetate; whereas, GC-MS captured total metabolite changes. Differences in the number of sample processing steps may also impart unintended variations. Metabolite derivatization has been identified as a major source of sample variation.^{10, 12, 14} Similarly, variable metabolite stability during GC-MS data acquisition is another potential source of error.¹⁵ Finally, a limited number of biological replicates will also contribute to a larger variance. We want to emphasize that given these unavoidable discrepancies, and the limited number of sample replicates, the observed correlation between the relative changes in metabolite concentration is quite notable. Importantly, the overall trend (or direction) in metabolite concentration change is preserved for the majority of metabolites despite the scatter in the magnitude of these changes. Furthermore, a simple comparison of metabolite trends is probably the limit of the data given the distinct and numerous sources of variance.

A pair-wise comparison between the 22 individual metabolites identified by both NMR and GC-MS are plotted as line curves in Figure S2. Again, an acceptable level of consistency is achieved in the pair-wise comparisons. A general agreement was also observed in the relative changes between both compound treatments. Any observed discrepancies between metabolite trends may be explained by the fact that GC-MS is capturing the total metabolite change while NMR is only capturing the changes in metabolites derived from $^{13}\text{C}_2$ -acetate. In this regards, both measurements are likely correct, but are simply observing different aspects of the metabolome. Again, this highlights the inherent strength of combining both NMR and MS. Conversely, if GC-MS observes a significantly lower metabolite concentration relative to NMR, this is a likely an error in the GC-MS data due to a limited thermal stability of the metabolite, variations in derivatization efficiency, and the multi-peak

phenomena.^{12–15} Additionally, given the fact that NMR routinely provides highly accurate sample quantitation relative to MS, NMR is likely to provide the correct metabolite change when the methods disagree (Figure S3).⁴¹

Extensive, nearly complete, coverage of key metabolic pathways associated with lipid accumulation was only achieved by combining NMR and GC-MS data. In effect, the NMR data filled-in the metabolites that were missed by GC-MS. Importantly, the broader coverage of the *C. reinhardtii* metabolome was able to provide a comprehensive view of the algae's response to a compound treatment. This level of detail is essential to further our understanding of the mechanism of action of drug-leads, of drug resistance, and of disease development and progression, among numerous other potential utilities. Achieving this level of coverage of the metabolome requires employing multiple analytical techniques. This viewpoint is consistent with some prior observations.^{8, 21–26} For example, Chen *et al.* noted an improvement in biomarker identification by combining 1D ¹H NMR and GC-MS for the analysis of urine from patients with bipolar disorder.⁴² Another recent example highlighted the use of 1D ¹H NMR and GC-MS for the analysis of bronchial wash fluid to investigate responsiveness to air pollution.⁴³ Barding *et al.* have highlighted similar improvements in coverage of the metabolome in molecular response of rice to stress.⁴⁴ These studies were able to combine multiple datasets to obtain a robust set of biomarkers, which further emphasizes the benefit of combining multiple analytical platforms for metabolomics. These are other recent examples where both NMR and GC-MS metabolomics datasets have been integrated for applications in biomarker identification, food chemistry and plant physiology.^{45–48}

To date, the majority of metabolomics studies have been self-limited to a single analytical platform (Figure 1). This is despite the fact that NMR and MS (and other analytical techniques) are highly complementary. Furthermore, existing workflows (Figure 2A) can easily accommodate the inclusion of both techniques. Consequently, there is little to no barrier to the broad adoption by the scientific community of a multi-analytical approach to metabolomics. Importantly and as clearly demonstrated herein, combining NMR and MS improves the coverage of the metabolome, increases the accuracy of metabolite assignments,^{19–21} and provides redundant validation of metabolite changes. In fact, our results demonstrate a limited overlap in the metabolites identified by both NMR and GC-MS. But, most metabolites in common did exhibit consistent trends in relative concentration changes, showcasing the robustness of the combined approach. Our results provide clear evidence that both NMR and MS are equally valuable and necessary for metabolomics studies; and that combining multiple analytical sources is essential to the future of metabolomics.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENT

We thank Dr. Martha Morton, the Director of the Research Instrumentation Facility in the Department of Chemistry at the University of Nebraska-Lincoln for her assistance with the NMR experiments. This material is based upon work supported by the National Science Foundation under Grant Number (1660921). This work was supported in

part by funding from the Redox Biology Center (P30 GM103335, NIGMS); and the Nebraska Center for Integrated Biomolecular Communication (P20 GM113126, NIGMS). The research was performed in facilities renovated with support from the National Institutes of Health (RR015468–01). Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.

REFERENCES

1. Powers R, The Current State of Drug Discovery and a Potential Role for NMR Metabolomics. *J. Med. Chem* 2014, 57 (14), 5860–5870. [PubMed: 24588729]
2. Bradley SA; Ouyang A; Purdie J; Smitka TA; Wang T; Kaerner A, Fermentanomics: Monitoring Mammalian Cell Cultures with NMR Spectroscopy. *Journal of the American Chemical Society* 2010, 132 (28), 9531–9533. [PubMed: 20578691]
3. von Reuss SH; Bose N; Srinivasan J; Yim JJ; Judkins JC; Sternberg PW; Schroeder FC, Comparative Metabolomics Reveals Biogenesis of Ascarosides, a Modular Library of Small-Molecule Signals in *C. elegans*. *Journal of the American Chemical Society* 2012, 134 (3), 1817–1824. [PubMed: 22239548]
4. Vizcaino MI; Engel P; Trautman E; Crawford JM, Comparative Metabolomics and Structural Characterizations Illuminate Colibactin Pathway-Dependent Small Molecules. *Journal of the American Chemical Society* 2014, 136 (26), 9244–9247. [PubMed: 24932672]
5. Kalisiak J; Trauger SA; Kalisiak E; Morita H; Fokin VV; Adams MWW; Sharpless KB; Siuzdak G, Identification of a New Endogenous Metabolite and the Characterization of Its Protein Interactions through an Immobilization Approach. *Journal of the American Chemical Society* 2009, 131 (1), 378–386. [PubMed: 19055353]
6. Espaillat A; Forsmo O; El Biari K; Björk R; Lemaitre B; Trygg J; Cañada FJ; de Pedro MA; Cava F, Chemometric Analysis of Bacterial Peptidoglycan Reveals Atypical Modifications That Empower the Cell Wall against Predatory Enzymes and Fly Innate Immunity. *Journal of the American Chemical Society* 2016, 138 (29), 9193–9204. [PubMed: 27337563]
7. Ali MRK; Wu Y; Han T; Zang X; Xiao H; Tang Y; Wu R; Fernández FM; El-Sayed MA, Simultaneous Time-Dependent Surface-Enhanced Raman Spectroscopy, Metabolomics, and Proteomics Reveal Cancer Cell Death Mechanisms Associated with Gold Nanorod Photothermal Therapy. *Journal of the American Chemical Society* 2016, 138 (47), 15434–15442. [PubMed: 27809520]
8. Marshall DD; Powers R, Beyond the paradigm: Combining mass spectrometry and nuclear magnetic resonance for metabolomics. *Prog. Nucl. Magn. Reson. Spectrosc* 2017, 100, 1–16. [PubMed: 28552170]
9. Kell DB, Metabolomics and systems biology: making sense of the soup. *Current Opinion in Microbiology* 2004, 7 (3), 296–307. [PubMed: 15196499]
10. Xu F; Zou L; Ong CN, Multiorigin of chromatographic peaks in derivatized GC/MS metabolomics: A confounder that influences metabolic pathway interpretation. *Journal of Proteome Research* 2009, 8 (12), 5657–5665. [PubMed: 19835423]
11. Kanani H; Chrysanthopoulos PK; Klapa MI, Standardizing GC-MS metabolomics. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences* 2008, 871 (2), 191–201. [PubMed: 18538643]
12. Halket JM; Waterman D; Przyborowska AM; Patel RKP; Fraser PD; Bramley PM, Chemical derivatization and mass spectral libraries in metabolic profiling by GC/MS and LC/MS/MS. *J. Exp. Bot* 2005, 56 (410), 219–243. [PubMed: 15618298]
13. Xu F; Zou L; Ong CN, Experiment-originated variations, and multi-peak and multi-origination phenomena in derivatization-based GC-MS metabolomics. *TrAC, Trends Anal. Chem* 2010, 29 (3), 269–280.
14. Moros G; Chatziioannou AC; Gika HG; Raikos N; Theodoridis G, Investigation of the derivatization conditions for GC-MS metabolomics of biological samples. *Bioanalysis* 2017, 9 (1), 53–65. [PubMed: 27921459]

15. Fang M; Ivanisevic J; Benton HP; Johnson CH; Patti GJ; Hoang LT; Uritboonthai W; Kurczy ME; Siuzdak G, Thermal Degradation of Small Molecules: A Global Metabolomic Investigation. *Analytical Chemistry* 2015, 87 (21), 10935–10941. [PubMed: 26434689]
16. Pan Z; Raftery D, Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. *Analytical and Bioanalytical Chemistry* 2007, 387 (2), 525–527. [PubMed: 16955259]
17. Bird SS; Sheldon DP; Gathungu RM; Vouros P; Kautz R; Matson WR; Kristal BS, Structural characterization of plasma metabolites detected via LC-electrochemical coulometric array using LC-UV fractionation, MS, and NMR. *Analytical Chemistry* 2012, 84 (22), 9889–9898. [PubMed: 23106399]
18. Forseth RR; Fox EM; Chung D; Howlett BJ; Keller NP; Schroeder FC, Identification of Cryptic Products of the Gliotoxin Gene Cluster Using NMR-Based Comparative Metabolomics and a Model for Gliotoxin Biosynthesis. *Journal of the American Chemical Society* 2011, 133 (25), 9678–9681. [PubMed: 21612254]
19. Wang C; He L; Li D-W; Bruschweiler-Li L; Marshall AG; Bruschweiler R, Accurate Identification of Unknown and Known Metabolic Mixture Components by Combining 3D NMR with Fourier Transform Ion Cyclotron Resonance Tandem Mass Spectrometry. *J. Proteome Res* 2017, 16 (10), 3774–3786. [PubMed: 28795575]
20. Bingol K; Bruschweiler R, Knowns and unknowns in metabolomics identified by multidimensional NMR and hybrid MS/NMR methods. *Curr. Opin. Biotechnol* 2017, 43, 17–24. [PubMed: 27552705]
21. Bingol K; Bruschweiler R, Two elephants in the room: new hybrid nuclear magnetic resonance and mass spectrometry approaches for metabolomics. *Curr. Opin. Clin. Nutr. Metab. Care* 2015, 18 (5), 471–477. [PubMed: 26154280]
22. Stryeck S; Madl T; Birner-Gruenberger R, Integrative metabolomics as emerging tool to study autophagy regulation. *Microb Cell* 2017, 4 (8), 240–258. [PubMed: 28845422]
23. Bruntz RC; Lane AN; Higashi RM; Fan TWM, Exploring cancer metabolism using stable isotope-resolved metabolomics (SIRM). *J. Biol. Chem* 2017, 292 (28), 11601–11609. [PubMed: 28592486]
24. Gonzalez-Dominguez A; Duran-Guerrero E; Fernandez-Recamales A; Lechuga-Sancho AM; Sayago A; Schwarz M; Segundo C; Gonzalez-Dominguez R, An Overview on the Importance of Combining Complementary Analytical Platforms in Metabolomic Research. *Curr. Top. Med. Chem. (Sharjah, United Arab Emirates)* 2017, 17 (30), 3289–3295.
25. Bingol K, Recent Advances in Targeted and Untargeted Metabolomics by NMR and MS/NMR Methods. *High Throughput* 2018, 7 (2).
26. Pan Z; Raftery D, Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. *Anal. Bioanal. Chem* 2007, 387 (2), 525–527. [PubMed: 16955259]
27. Bingol K; Bruschweiler R, NMR/MS translator for the enhanced simultaneous analysis of metabolomics mixtures by NMR spectroscopy and mass spectrometry: Application to human urine. *Journal of Proteome Research* 2015, 14 (6), 2642–2648. [PubMed: 25881480]
28. Bingol K; Bruschweiler-Li L; Yu C; Somogyi A; Zhang F; Bruschweiler R, Metabolomics beyond Spectroscopic Databases: A Combined MS/NMR Strategy for the Rapid Identification of New Metabolites in Complex Mixtures. *Analytical Chemistry* 2015, 87 (7), 3864–3870. [PubMed: 25674812]
29. Baker JM; Ward JL; Beale MH, Combined NMR and Flow Injection ESI-MS for brassicaceae metabolomics. In *Methods in Molecular Biology*, 2012; Vol. 860, pp 177–191. [PubMed: 22351178]
30. Marshall DD; Lei S; Worley B; Huang Y; Garcia-Garcia A; Franco R; Dodds ED; Powers R, Combining DI-ESI-MS and NMR datasets for metabolic profiling. *Metabolomics* 2015, 11 (2), 391–402. [PubMed: 25774104]
31. Farag MA; Porzel A; Schmidt J; Wessjohann LA, Metabolite profiling and fingerprinting of commercial cultivars of *Humulus lupulus* L. (hop): a comparison of MS and NMR methods in metabolomics. *Metabolomics* 2012, 8 (3), 492–507.

32. Markley JL; Brüschweiler R; Edison AS; Eghbalnia HR; Powers R; Raftery D; Wishart DS, The future of NMR-based metabolomics. *Current Opinion in Biotechnology* 2017, 43, 34–40. [PubMed: 27580257]
33. Wase N; Tu B; Allen JW; Black PN; DiRusso CC, Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae. *Plant Physiology* 2017, 174 (4), 2146. [PubMed: 28652262]
34. Domingo-Almenara X; Brezmes J; Vinaixa M; Samino S; Ramirez N; Ramon-Krauel M; Lerin C; Diaz M; Ibanez L; Correig X; Perera-Lluna A; Yanes O, eRah: A Computational Tool Integrating Spectral Deconvolution and Alignment with Quantification and Identification of Metabolites in GC/MS-Based Metabolomics. *Anal Chem* 2016, 88 (19), 9821–9829. [PubMed: 27584001]
35. Delaglio F; Grzesiek S; Vuister GW; Zhu G; Pfeifer J; Bax A, NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR* 1995, 6 (3), 277–93. [PubMed: 8520220]
36. Johnson BA; Johnson BA, From Raw Data to Protein Backbone Chemical Shifts Using NMRFX Processing and NMRViewJ Analysis. *Methods Mol Biol* 2018, 1688, 257–310. [PubMed: 29151214]
37. Ulrich EL; Akutsu H; Doreleijers JF; Harano Y; Ioannidis YE; Lin J; Livny M; Mading S; Maziuk D; Miller Z; Nakatani E; Schulte CF; Tolmie DE; Kent Wenger R; Yao H; Markley JL, BioMagResBank. *Nucleic Acids Research* 2008, 36.
38. Kopka J; Schauer N; Krueger S; Birkemeyer C; Usadel B; Bergmüller E; Dörmann P; Weckwerth W; Gibon Y; Stitt M; Willmitzer L; Fernie AR; Steinhauser D, GMD@CSB.DB: the Golm Metabolome Database. *Bioinformatics* 2005, 21 (8), 1635–1638. [PubMed: 15613389]
39. Worley B; Powers R, MVAPACK: A complete data handling package for NMR metabolomics. *ACS Chemical Biology* 2014, 9 (5), 1138–1144. [PubMed: 24576144]
40. Bingol K; Li D-W; Bruschiweiler-Li L; Cabrera OA; Megraw T; Zhang F; Bruschiweiler R, Unified and Isomer-Specific NMR Metabolomics Database for the Accurate Analysis of ¹³C-1H HSQC Spectra. *ACS Chem. Biol* 2015, 10 (2), 452–459. [PubMed: 25333826]
41. Malz F; Jancke H, Validation of quantitative NMR. *J. Pharm. Biomed. Anal* 2005, 38 (5), 813–823. [PubMed: 15893442]
42. Chen J; Liu Z; Fan S; Yang D; Zheng P; Shao W; Qi Z; Xu X; Li Q; Mu J; Yang Y; Xie P, Combined Application of NMR- and GC-MS-Based Metabonomics Yields a Superior Urinary Biomarker Panel for Bipolar Disorder. *Scientific Reports* 2014, 4, 5855. [PubMed: 25068480]
43. Surowiec I; Karimpour M; Gouveia-Figueira S; Wu J; Unosson J; Bosson JA; Blomberg A; Pourazar J; Sandström T; Behndig AF; Trygg J; Nording ML, Multi-platform metabolomics assays for human lung lavage fluids in an air pollution exposure study. *Analytical and Bioanalytical Chemistry* 2016, 408 (17), 4751–4764. [PubMed: 27113461]
44. Barding GA; Béni S; Fukao T; Bailey-Serres J; Larive CK, Comparison of GC-MS and NMR for Metabolite Profiling of Rice Subjected to Submergence Stress. *Journal of Proteome Research* 2013, 12 (2), 898–909. [PubMed: 23205590]
45. Griffith CM; Morgan MA; Dinges MM; Mathon C; Larive CK, Metabolic Profiling of Chloroacetanilide Herbicides in Earthworm Coelomic Fluid Using (1)H NMR and GC-MS. *J Proteome Res* 2018, 17 (8), 2611–2622. [PubMed: 29939029]
46. Kumar A; Maurya AK; Chand G; Agnihotri VK, Comparative metabolic profiling of *Costus speciosus* leaves and rhizomes using NMR, GC-MS and UPLC/ESI-MS/MS. *Natural product research* 2018, 32 (7), 826–833. [PubMed: 28814124]
47. Tomita S; Nakamura T; Okada S, NMR- and GC/MS-based metabolomic characterization of sunki, an unsalted fermented pickle of turnip leaves. *Food chemistry* 2018, 258, 25–34. [PubMed: 29655730]
48. Trimigno A; Munger L; Picone G; Freiburghaus C; Pimentel G; Vionnet N; Pralong F; Capozzi F; Badertscher R; Vergeres G, GC-MS Based Metabolomics and NMR Spectroscopy Investigation of Food Intake Biomarkers for Milk and Cheese in Serum of Healthy Humans. *Metabolites* 2018, 8 (2).




Figure 1.
A summary of metabolomics publications in PubMed that only refer to NMR (yellow), to GC-MS (blue) or to both GC-MS and NMR (grey).




Figure 2.

(A) A workflow schematic showing the key steps in the combined NMR and GC-MS analysis of the *C. reinhardtii* metabolome. Three biological replicates were prepared for each group consisting of the untreated controls, WD30030 treated cells, and WD10784 treated cells. A GC-MS spectrum and a 2D ¹H-¹³C HSQC NMR spectrum were collected for each biological replicate. (B) Multiblock PCA scores plot generated from the combined GC-MS and 2D ¹H-¹³C HSQC NMR datasets illustrating a distinct clustering for untreated controls (■) and the WD30030 (■) and WD10784 (■) treated cells. Three biological replicates are displayed per group, where each data point represents the combined GC-MS and 2D ¹H-¹³C HSQC NMR datasets plotted in PC-space. The ellipses represent a 95% confidence limit of the normal distribution of each cluster. The associated dendrogram was derived from the PCA scores plot and each node is annotated with a Mahalanobis distance-based p-value. The separation between untreated controls and WD30030 (p-value 2.5×10^{-3}) and WD10784 (p-value 8.9×10^{-4}), respectively, is considered statistically significant ($p < 0.05$). The color scheme for the dendrogram is the same as the scores plot.




Figure 3. Metabolic pathway summarizing the coverage of the *C. reinhardtii* metabolome (metabolites of interest) from the combined application of NMR and GC-MS. Metabolites that were only identified by NMR are colored blue. Metabolites that were only identified by GC-MS are colored red. Metabolites identified by both methods are colored black, and metabolites not identified are colored grey. The embedded Venn diagram identifies the total number of metabolites of interest within these metabolic pathways that were identified by either NMR, by GC-MS or by both techniques.




Figure 4.

A comparison of the 22 relative metabolite concentration changes detected by NMR and GC-MS. Metabolite changes resulting from treatment with WD30030 and WD10784 are colored green or blue, respectively. The regression line fitted to the data exhibited a correlation coefficient of R^2 0.55 and confidence interval with a p-value < 0.001.